Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: jayhawk969 who wrote (5893)	3/13/2002 2:41:08 PM
From: Biomaven	Read Replies (3) \| Respond to of 52153

they would be much tougher on non-critical applications. By my read Bexar would save lives. This might actually be a good situation for CRXA to try the appeals process. Certainly the abstracts and presentations we saw seemed to indicate the drug was effective. Of course with Zevalin's approval the pressure on the FDA for Bexxar's approval lessened considerably. Patients who fail Rituxan now have someplace to go. I bought a little IDPH on the Bexxar news. They have to be helped susbstantially by this delay, and perhaps more important, they already have their FDA approvals. Peter